A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7d prior to transfusion

British Journal of Haematology

Volumn 153, Issue 3, 2011, Pages 393-401

  Lozano, Miguel ^a   Knutson, Folke ^b   Tardivel, René ^c   Cid, Joan ^a,d   Maymó, Rosa Maria ^d   Löf, Helena ^b   Roddie, Huw ^e   Pelly, Jane ^f   Docherty, Anthony ^f   Sherman, Claire ^g   Lin, Lily ^g   Propst, Meisa ^g   Corash, Laurence ^g   Prowse, Chris ^f  

^a HOSPITAL CLÍNIC   (Spain)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d BANC DE SANG I TEIXITS   (Spain)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^g CERUS CORPORATION   (United States)

Author keywords

Amotosalen; Pathogen inactivation; Platelet storage; Platelet transfusion; Transfusion medicine

Indexed keywords

AMOTOSALEN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BLEEDING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE TRANSFUSION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATHOGEN INACTIVATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSFUSION RELATED SEPSIS; TREATMENT DURATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

ADOLESCENT; ADULT; AGED; BLOOD PLATELETS; BLOOD PRESERVATION; CELL AGING; DOUBLE-BLIND METHOD; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOSTASIS; HUMANS; MALE; MICROBIAL VIABILITY; MIDDLE AGED; PLATELET COUNT; PLATELET TRANSFUSION; PROSPECTIVE STUDIES; PSORALENS; TIME FACTORS; TREATMENT OUTCOME; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 79954421646     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08635.x     Document Type: Article

References (31)

1. Bishop, J.F., Matthews, J.P., Mcgrath, K., Yuen, K., Wolf, M.M. & Szer, J. (1991) Factors influencing 20-hour increments after platelet transfusion. Transfusion, 31, 392-396.
2. Cawley, C., McDonald, C., Ancliff, S., Roy, A., Maclennan, S., Brant, L., Pichon, B. & Brailsford, S. (2011) Early recognition and reporting of suspected bacterial contamination may prevent transfusion transmission of infection by associated units. Transfusion Medicine, 21, 70-72.
3. Cazenave, J.P., Waller, C., Kientz, D., Mendel, I., Lin, L., Jacquet, M., Propst, M., Liu, W., Corash, L., Sundin, D., Defoin, L., Messe, N. & Osselaer, J.C. (2010) An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion, 50, 1210-1219.
4. Cognasse, F., Osselaer, J.C., Payrat, J.M., Chavarin, P., Corash, L. & Garraud, O. (2008) Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion, 48, 809-813.
5. Davis, K.B., Slichter, S.J. & Corash, L. (1999) Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion, 39, 586-592.
6. Dumont, L.J., Kleinman, S., Murphy, J.R., Lippincott, R., Schuyler, R., Houghton, J. & Metzel, P. (2010) Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion, 50, 589-599.
7. Eder, A.F., Kennedy, J.M., Dy, B.A., Notari, E.P., Skeate, R., Bachowski, G., Mair, D.C., Webb, J.S., Wagner, S.J., Dodd, R.Y. & Benjamin, R.J. (2009) Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion, 49, 1554-1563.
8. Esber, E. (1986) Reduction of the Maximum Platelet Storage Period to 5Days in an Approved Container. FDA memorandum U.S. Food and Drug Administration, Rockville, MD, USA.
9. Grass, J.A., Hei, D.J., Metchette, K., Cimino, G.D., Wiesehahn, G.P., Corash, L. & Lin, L. (1998) Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood, 91, 2180-2188.
10. Janetzko, K., Cazenave, J.P., Kluter, H., Kientz, D., Michel, M., Beris, P., Lioure, B., Hastka, J., Marblie, S., Mayaudon, V., Lin, L., Lin, J.S., Conlan, M.G. & Flament, J. (2005) Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion, 45, 1443-1452.
11. Kerkhoffs, J.L., Eikenboom, J.C., Schipperus, M.S., Wordragen-Vlaswinkel, R.J., Brand, R., Harvey, M.S., de Vries, R.R., Barge, R., van Rhenen, D.J. & Brand, A. (2006) A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood, 108, 3210-3215.
12. Kerkhoffs, J.L., van Putten, W.L., Novotny, V.M., te Boekhorst, P.A., Schipperus, M.R., Zwaginga, J.J., van Pampus, L.C., de Greef, G.E., Luten, M., Huijgens, P.C., Brand, A. & van Rhenen, D.J. (2010) Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. British Journal of Haematology, 150, 209-217.
13. Lin, L., Cook, D.N., Wiesehahn, G.P., Alfonso, R., Behrman, B., Cimino, G.D., Corten, L., Damonte, P.B., Dikeman, R., Dupuis, K., Fang, Y.M., Hanson, C.V., Hearst, J.E., Lin, C.Y., Londe, H.F., Metchette, K., Nerio, A.T., Pu, J.T., Reames, A.A., Rheinschmidt, M., Tessman, J., Isaacs, S.T., Wollowitz, S. & Corash, L. (1997) Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion, 37, 423-435.
14. Lin, L., Hanson, C.V., Alter, H.J., Jauvin, V., Bernard, K.A., Murthy, K.K., Metzel, P. & Corash, L. (2005) Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion, 45, 580-590.
15. Lozano, M., Galan, A., Mazzara, R., Corash, L. & Escolar, G. (2007) Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7days: assessment of hemostatic function under flow conditions. Transfusion, 47, 666-671.
16. McCullough, J., Vesole, D.H., Benjamin, R.J., Slichter, S.J., Pineda, A., Snyder, E., Stadtmauer, E.A., Lopez-Plaza, I., Coutre, S., Strauss, R.G., Goodnough, L.T., Fridey, J.L., Raife, T., Cable, R., Murphy, S., Howard, F., Davis, K., Lin, J.S., Metzel, P., Corash, L., Koutsoukos, A., Lin, L., Buchholz, D.H. & Conlan, M.G. (2004) Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood, 104, 1534-1541.
17. Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47, 207-214.
18. Murphy, S. (2002) What's so bad about old platelets? Transfusion, 42, 809-811.
19. Murphy, S. & Gardner, F.H. (1975) Platelet storage at 22 degrees C: role of gas transport across plastic containers in maintenance of viability. Blood, 46, 209-218.
20. Murphy, W.G., Foley, M., Doherty, C., Tierney, G., Kinsella, A., Salami, A., Cadden, E. & Coakley, P. (2008) Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sanguinis, 95, 13-19.
21. Novak, M. (1939) Preservation of stored blood with sulfanilamide. Journal of American Medical Association, 113, 2227-2229.
22. Nussbaumer, W., Allersdorfer, D., Grabmer, C., Rheinschmidt, M., Lin, L., Schonitzer, D. & Lass-Florl, C. (2007) Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods. Transfusion, 47, 1125-1133.
23. Osselaer, J.C., Doyen, C., Defoin, L., Debry, C., Goffaux, M., Messe, N., Van Hooydonk, M., Bosly, A., Lin, J.S., Lin, L. & Corash, L. (2009) Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion, 49, 1412-1422.
24. Pearce, S., Rowe, G.P. & Field, S.P. (2011) Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfusion Medicine, 21, 25-32.
25. van Rhenen, D.J., Vermeij, J., Mayaudon, V., Hind, C., Lin, L. & Corash, L. (2000) Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sanguinis, 79, 206-214.
26. van Rhenen, D., Gulliksson, H., Cazenave, J.P., Pamphilon, D., Ljungman, P., Kluter, H., Vermeij, H., Kappers-Klunne, M., de Greef, G., Laforet, M., Lioure, B., Davis, K., Marblie, S., Mayaudon, V., Flament, J., Conlan, M., Lin, L., Metzel, P., Buchholz, D. & Corash, L. (2003) Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood, 101, 2426-2433.
27. Simonsen, A.C., Johansson, P.I., Conlan, M.G., Jacquet, M., Lin, J.S., Junge, K., Lin, L., Sorensen, H., Borregaard, N. & Flament, J. (2006) Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion, 46, 424-433.
28. Slichter, S.J., Raife, T.J., Davis, K., Rheinschmidt, M., Buchholz, D.H., Corash, L. & Conlan, M.G. (2006) Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion, 46, 731-740.
29. Slichter, S.J., Kaufman, R.M., Assmann, S.F., McCullough, J., Triulzi, D.J., Strauss, R.G., Gernsheimer, T.B., Ness, P.M., Brecher, M.E., Josephson, C.D., Konkle, B.A., Woodson, R.D., Ortel, T.L., Hillyer, C.D., Skerrett, D.L., Mccrae, K.R., Sloan, S.R., Uhl, L., George, J.N., Aquino, V.M., Manno, C.S., Mcfarland, J.G., Hess, J.R., Leissinger, C. & Granger, S. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. New England Journal of Medicine, 362, 600-613.
30. 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion, 44, 1732-1740.
31. Snyder, E., McCullough, J., Slichter, S.J., Strauss, R.G., Lopez-Plaza, I., Lin, J.S., Corash, L. & Conlan, M.G. (2005) Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion, 45, 1864-1875.